|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ghosh P and Chin L: Genetics and genomics
of melanoma. Expert Rev Dermatol. 4:1312009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balch CM, Soong SJ, Gershenwald JE, et al:
Prognostic factors analysis of 17,600 melanoma patients: Validation
of the American Joint Committee on Cancer melanoma staging system.
J Clin Oncol. 19:3622–3634. 2001.PubMed/NCBI
|
|
4
|
Barth A, Wanek LA and Morton DL:
Prognostic factors in 1,521 melanoma patients with distant
metastases. J Am Coll Surg. 181:193–201. 1995.PubMed/NCBI
|
|
5
|
Hontscha C, Borck Y, Zhou H, Messmer D and
Schmidt-Wolf IG: Clinical trials on CIK cells: First report of the
international registry on CIK cells (IRCC). J Cancer Res Clin
Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schwaab T, Schwarzer A, Wolf B, et al:
Clinical and immunologic effects of intranodal autologous tumor
lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and
IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.
Clin Cancer Res. 15:4986–4992. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosenberg SA, Spiess P and Lafreniere R: A
new approach to the adoptive immunotherapy of cancer with
tumor-infiltrating lymphocytes. Science. 233:1318–1321. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosenberg S: Lymphokine-activated killer
cells: A new approach to immunotherapy of cancer. J Natl Cancer
Inst. 75:595–603. 1985.PubMed/NCBI
|
|
9
|
Yun YS, Hargrove ME and Ting CC: In vivo
antitumor activity of anti-CD3-induced activated killer cells.
Cancer Res. 49:4770–4774. 1989.PubMed/NCBI
|
|
10
|
Shablak A, Hawkins RE, Rothwell DG and
Elkord E: T cell-based immunotherapy of metastatic renal cell
carcinoma: Modest success and future perspective. Clin Cancer Res.
15:6503–6510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume
KG and Weissman IL: Use of a SCID mouse/human lymphoma model to
evaluate cytokine-induced killer cells with potent antitumor cell
activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li R, Wang C, Liu L, et al: Autologous
cytokine-induced killer cell immunotherapy in lung cancer: a phase
II clinical study. Cancer Immunol Immunother. 61:2125–2133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi L, Zhou Q, Wu J, et al: Efficacy of
adjuvant immunotherapy with cytokine-induced killer cells in
patients with locally advanced gastric cancer. Cancer Immunol
Immunother. 61:2251–2259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu L, Zhang W, Qi X, et al: Randomized
study of autologous cytokine-induced killer cell immunotherapy in
metastatic renal carcinoma. Clin Cancer Res. 18:1751–1759. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hersey P: Immunotherapy of melanoma. Asia
Pac J Clin Oncol. 6 Suppl:1:S2–S8. 2010. View Article : Google Scholar
|
|
16
|
Schmidt-Wolf IG, Finke S, Trojaneck B, et
al: Phase I clinical study applying autologous immunological
effector cells transfected with the interleukin-2 gene in patients
with metastatic renal cancer, colorectal cancer and lymphoma. Br J
Cancer. 81:1009–1016. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang J, Xu N, Wu C, et al: Treatment of
advanced gastric cancer by chemotherapy combined with autologous
cytokine-induced killer cells. Anticancer Res. 26 (3B):2237–2242.
2006.PubMed/NCBI
|
|
18
|
Wu C, Jiang J, Shi L and Xu N: Prospective
study of chemotherapy in combination with cytokine-induced killer
cells in patients suffering from advanced non-small cell lung
cancer. Anticancer Res. 28 (6B):3997–4002. 2008.PubMed/NCBI
|
|
19
|
Hui D, Qiang L, Jian W, Ti Z and Da-Lu K:
A randomized, controlled trial of postoperative adjuvant
cytokine-induced killer cells immunotherapy after radical resection
of hepatocellular carcinoma. Dig Liver Dis. 41:36–41. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li W, Xu LP, DI Zhao L, et al:
Cytokine-induced killer cell therapy for advanced pancreatic
adenocarcinoma: A case report and review of the literature. Oncol
Lett. 5:1427–1429. 2013.PubMed/NCBI
|
|
21
|
Huang ZM, Li W, Li S, et al:
Cytokine-induced killer cells in combination with transcatheter
arterial chemoembolization and radiofrequency ablation for
hepatocellular carcinoma patients. J Immunother. 36:287–293. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alexandrescu DT, Ichim TE, Riordan NH, et
al: Immunotherapy for melanoma: Current status and perspectives. J
Immunother. 33:570–590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Robert C, Long GV, Brady B, et al:
Nivolumab in previously untreated melanoma without BRAF mutation. N
Engl J Med. 372:320–330. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao Q, Zhang H, Li Y, Liu J, Hu X and Fan
L: Anti-tumor effects of CIK combined with oxaliplatin in human
oxaliplatin-resistant gastric cancer cells in vivo and in vitro. J
Exp Clin Cancer Res. 29:1182010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang FS, Liu MX, Zhang B, et al: Antitumor
activities of human autologous cytokine-induced killer (CIK) cells
against hepatocellular carcinoma cells in vitro and in vivo. World
J Gastroenterol. 8:464–468. 2002.PubMed/NCBI
|
|
26
|
Zhang YS, Yuan FJ, Jia GF, et al: CIK
cells from patients with HCC possess strong cytotoxicity to
multidrug-resistant cell line Bel-7402/R. World J Gastroenterol.
11:3339–3345. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Karimi M, Cao TM, Baker JA, Verneris MR,
Soares L and Negrin RS: Silencing human NKG2D, DAP10 and DAP12
reduces cytotoxicity of activated CD8+ T cells and NK cells. J
Immunol. 175:7819–7828. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Verneris MR, Karami M, Baker J, Jayaswal A
and Negrin RS: Role of NKG2D signaling in the cytotoxicity of
activated and expanded CD8+ T cells. Blood. 103:3065–3072. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schmidt-Wolf IG, Lefterova P, Mehta BA, et
al: Phenotypic characterization and identification of effector
cells involved in tumor cell recognition of cytokine-induced killer
cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
|
|
30
|
Joshi PS, Liu JQ, Wang Y, et al:
Cytokine-induced killer T cells kill immature dendritic cells by
TCR-independent and perforin-dependent mechanisms. J Leukoc Biol.
80:1345–1353. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gammaitoni L, Giraudo L, Leuci V, et al:
Effective activity of cytokine-induced killer cells against
autologous metastatic melanoma including cells with stemness
features. Clin Cancer Res. 19:4347–4358. 2013. View Article : Google Scholar : PubMed/NCBI
|
